ReviewJournal of mammary gland biology and neoplasia2010
Epigenetic regulation in estrogen receptor positive breast cancer--role in treatment response.
Review in Journal of mammary gland biology and neoplasia, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Global View of Candidate Therapeutic Target Genes in Hormone-Responsive Breast Cancer.International journal of molecular sciences · 2020Review
- Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers.Advanced biomedical research · 2019Review
- Exploring the Pharmacological Mechanism of Danzhi Xiaoyao Powder on ER-Positive Breast Cancer by a Network Pharmacology Approach.Evidence-based complementary and alternative medicine : eCAM · 2018Article
- Polyphenols as Promising Drugs against Main Breast Cancer Signatures.Antioxidants (Basel, Switzerland) · 2017Review
- Epigenetic Mechanisms of Tamoxifen Resistance in Luminal Breast Cancer.Diseases (Basel, Switzerland) · 2017Review
- Luminal STAT5 mediates H2AX promoter activity in distinct population of basal mammary epithelial cells.Oncotarget · 2016Article
- CDH1 promoter methylation correlates with decreased gene expression and poor prognosis in patients with breast cancer.Oncology letters · 2016Article
- The changing role of ER in endocrine resistance.Breast (Edinburgh, Scotland) · 2015Review
- Role of epigenetic modifications in luminal breast cancer.Epigenomics · 2015Review
- Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.Breast cancer research : BCR · 2015Article
- Epigenetics in breast and prostate cancer.Methods in molecular biology (Clifton, N.J.) · 2015Review
- PELP1 oncogenic functions involve CARM1 regulation.Carcinogenesis · 2013Article
- Derailed estrogen signaling and breast cancer: an authentic couple.Endocrine reviews · 2013Review
- Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.International journal of molecular sciences · 2012Review
- DNA methylation profiling reveals a predominant immune component in breast cancers.EMBO molecular medicine · 2011Article
- Assessing estrogen signaling aberrations in breast cancer risk using genetically engineered mouse models.Annals of the New York Academy of Sciences · 2011Review
- Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011Article
- Epigenetics of estrogen receptor signaling: role in hormonal cancer progression and therapy.Cancers · 2011Article
- Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole.Cancer research · 2011Article
- Epigenetics in breast cancer: what's new?Breast cancer research : BCR · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Recent advances in breast cancer treatment have allowed increasing numbers of patients with estrogen receptor (ER) positive (+) breast cancer to receive various forms of endocrine therapy. Unfortunately, de novo and acquired resistance to endocrine therapy remains a major challenge in the clinic. A number of possible mechanisms for drug resistance have been described, which include activation of growth factor receptor pathways, overexpression of ER coactivators, and metabolic resistance due to polymorphisms in metabolizing enzymes. While many of these changes are caused by genetic alterations, there is also increasing evidence to implicate epigenetic gene regulatory mechanisms in the development of endocrine resistance. Since epigenetic modifications are easier to reverse than genetic mutations, they are appealing therapeutic targets, and thus future improvements in medical care for breast cancer patients will depend upon a better understanding of the roles epigenetic modifications play in endocrine resistance. In this review we will focus on recent advances made in the understanding of epigenetic gene regulation in estrogen response and endocrine resistance in breast cancer. We will also summarize current clinical-translational advances in epigenetic therapy, and discuss potential future clinical use of epigenetic changes as therapeutic targets, especially with respect to endocrine treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.